KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN) today announced financial results for the quarter ended September 30, 2016 and provided an update regarding its ongoing clinical programs.
“This quarter saw important progress for our company, with continued execution of our Phase 3 program for oliceridine.
“This quarter saw important progress for our company, with continued execution of our Phase 3 program for oliceridine.
